Literature DB >> 31501878

The Influence of Microscopic Inflammation at Resection Margins on Early Postoperative Endoscopic Recurrence After Ileocaecal Resection for Crohn's Disease.

Karolina Poredska1, Lumir Kunovsky1,2, Filip Marek2, Zdenek Kala2, Vladimir Prochazka2, Jiri Dolina1, Vladimir Zboril1, Petra Kovalcikova3, Tomas Pavlik3, Petr Jabandziev4, Zdenek Pavlovsky5, Jakub Vlazny5, Ladislav Mitas2.   

Abstract

BACKGROUND AND AIMS: The pathogenesis and risk factors for early postoperative endoscopic recurrence of Crohn's disease [CD] remain unclear. Thus, this study aimed to identify whether histological inflammation at the resection margins after an ileocaecal resection influences endoscopic recurrence.
METHODS: We have prospectively followed up patients with CD who underwent ileocaecal resection at our hospital between January 2012 and January 2018. The specimens were histologically analysed for inflammation at both of the resection margins [ileal and colonic]. We evaluated whether histological results of the resection margins are correlated with endoscopic recurrence of CD based on colonoscopy 6 months after ileocaecal resection. Second, we assessed the influence of known risk factors and preoperative therapy on endoscopic recurrence of CD.
RESULTS: A total of 107 patients were included in our study. Six months after ileocaecal resection, 23 patients [21.5%] had an endoscopic recurrence of CD. The histological signs of CD at the resection margins were associated with a higher endoscopic recurrence [56.5% versus 4.8%, p < 0.001]. Disease duration from diagnosis to surgery [p = 0.006] and the length of the resected bowel [p = 0.019] were significantly longer in patients with endoscopic recurrence. Smoking was also proved to be a risk factor for endoscopic recurrence [p = 0.028].
CONCLUSIONS: Histological inflammation at the resection margins was significantly associated with a higher risk of early postoperative endoscopic recurrence after an ileocaecal resection for CD. © European Crohn’s and Colitis Organisation (ECCO) 2019.

Entities:  

Keywords:  Crohn’s disease; early postoperative endoscopic recurrence; ileocaecal resection

Mesh:

Year:  2020        PMID: 31501878     DOI: 10.1093/ecco-jcc/jjz153

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  6 in total

1.  Does microscopic involvement of the surgical margins after ileocecectomy in Crohn's patients predict early recurrence?

Authors:  Meir Zemel; Elian Solo; Hagit Tulchinsky
Journal:  Int J Colorectal Dis       Date:  2021-04-29       Impact factor: 2.571

Review 2.  The Role of Inflammation in Crohn's Disease Recurrence after Surgical Treatment.

Authors:  B Sensi; L Siragusa; C Efrati; L Petagna; M Franceschilli; V Bellato; A Antonelli; C Arcudi; M Campanelli; S Ingallinella; A M Guida; A Divizia
Journal:  J Immunol Res       Date:  2020-12-26       Impact factor: 4.818

Review 3.  Medical therapies for postoperative Crohn's disease.

Authors:  Ravi S Shah; Benjamin H Click
Journal:  Therap Adv Gastroenterol       Date:  2021-02-15       Impact factor: 4.409

Review 4.  Surgical Strategies to Reduce Postoperative Recurrence of Crohn's Disease After Ileocolic Resection.

Authors:  Ian S Reynolds; Katie L Doogan; Éanna J Ryan; Daniel Hechtl; Frederik P Lecot; Shobhit Arya; Sean T Martin
Journal:  Front Surg       Date:  2021-12-17

5.  It is not NOD2 - genetic and clinical risk factors for postoperative complications following ileocolic resection in Crohn's disease.

Authors:  Josefine Schardey; Sophie Zehl; Alina S Kappenberger; Petra Zimmermann; Florian Beigel; Tobias S Schiergens; Michael S Kasparek; Florian Kühn; Jens Werner; Ulrich Wirth
Journal:  Int J Colorectal Dis       Date:  2022-08-01       Impact factor: 2.796

6.  Outcomes of Primary Ileocolic Resection for Pediatric Crohn Disease in the Biologic Era.

Authors:  Elizabeth A Spencer; Lauren Jarchin; Priya Rolfes; Sergey Khaitov; Alexander Greenstein; Marla C Dubinsky
Journal:  J Pediatr Gastroenterol Nutr       Date:  2021-12-01       Impact factor: 2.839

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.